Oslo, 21 December 2018 - Navamedic ASA (Navamedic, OSE: NAVA) today announces
that the Board of Directors has appointed Kathrine Gamborg Andreassen as Chief
Executive Officer. Ms. Gamborg Andreassen will assume her position effective
January 1, 2019.
"I am pleased to announce Kathrine Gamborg Andreassen as the new CEO of
Navamedic. Kathrine is a seasoned and experienced executive with an impressive
track record in the pharma and healthcare field. Adding in her experience as the
company's former Chair of the Board, we are confident that Kathrine will utilise
Navamedic's stong platform to bring new growth and value creation to the
company," says Terje Bakken, Chairman of the Board of Directors.
Kathrine Gamborg Andreassen served as Chair of the Board of Navamedic from June
until December 2018. Gamborg Andreassen was the CEO of Weifa ASA until the
company was acquired by Karo Pharma AB in November 2017, and also served as VP
Consumer Health at Weifa. Gamborg Andreassen is the co-owner and Chair of the
Board at Novicus Pharma AS. She holds a Msc in Business Strategy & Marketing
from the University of Wisconsin at Madison and a BBA from Handelsakademiet/Oslo
Business School.
Kathrine Gamborg Andreassen will assume her position as CEO of Navamedic
effective January 1, 2019.
For further information, please contact:
Toril Ås, Chief Financial Officer at Navamedic
toril.as@navamedic.com, +47 671 12 540
Navamedic ASA is a Norwegian company within pharmaceuticals and medical
technology, delivering products to patients, hospitals and pharmacies in the
Nordic and selected European markets. Navamedic's business unit for
pharmaceutical and healthcare products is a distributor of products supplied by
a number of pharmaceutical manufacturers. Navamedic's business within medical
technology has developed and is currently introducing Sippi®, a new system for
digital urine measurement. Navamedic is listed on the Oslo Stock Exchange
(ticker: NAVA).
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.